Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency.

Area of Science:

• Hematology
• Thrombosis Research
• Pharmacology

Background:

• Factor XI (FXI) deficiency increases bleeding risk during surgery.
• Plasma-derived FXI replacement carries risks like infection and thrombosis.
• An effective and safer alternative for surgical bleeding prevention is needed.

Purpose of the Study:

• To evaluate recombinant factor VIIa (rFVIIa) as a hemostatic agent in patients with FXI deficiency undergoing surgical procedures.
• To assess the efficacy and safety of rFVIIa in preventing surgical bleeding in this patient population.

Main Methods:

• Fourteen patients with FXI deficiency (severe and partial) received rFVIIa for major, minor, and dental procedures.
• Specific dosing regimens were used for different surgery types, with oral tranexamic acid postoperatively.
• Hemostasis was monitored, and adverse events were recorded.

Main Results:

• All patients achieved effective hemostasis, eliminating the need for alternative agents or transfusions.
• Three adverse events occurred: cerebrovascular accident, allergic reaction, and phlebitis.
• rFVIIa demonstrated efficacy in preventing surgical bleeding across various procedures.

Conclusions:

• Recombinant factor VIIa (rFVIIa) is an effective hemostatic alternative for Factor XI (FXI) deficient patients undergoing surgery.
• rFVIIa may not be suitable for patients with pre-existing thrombosis risk factors.
• Further research into the safety profile of rFVIIa in specific patient groups is warranted.